This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Transfusion-Dependent β-Thalassemia > Efficacy > Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms)
Print

In this section:

Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms) Severe Cardiac Iron Toxicity (T2* <10 ms) Preventing Cardiac Iron Loading (T2* >20 ms) EPIC 1-Year
Cardiac Substudy
EU SmPC
Mild to Moderate Cardiac Iron Toxicity

Total Body Iron Chelation in Patients With Mild to Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms)

EXJADE improved cardiac iron burden as measured by myocardial T2* in patients who were switched from other chelators1

Learn more about the cardiac
substudy of the EPIC
clinical trial.

T2* Improvements Above the Normal Cardiac Iron Threshold
in Patients With Mild-Moderate Cardiac Iron Levels
Prevention Threshold Chart

Three-year results of the EPIC cardiac substudy myocardial siderosis (N=101). The investigators assessed the efficacy and safety of EXJADE in removing myocardial iron in heavily transfused patients with β-thalassemia1

  • T2* threshold of 20 ms was crossed by 2 years1
  • 68% of patients with mild-moderate cardiac iron severity achieved normal cardiac iron levels (T2* ≥20 ms)1

EXJADE provides serum ferritin and liver iron concentration reductions early that continue with treatment2

Three-year data from the EPIC cardiac substudy showed continuous reductions in serum ferritin and liver iron concentration levels.


Continued LIC and Serum Ferritin Reductions Over 3 Years (n=47)1
Continued LIC & Serum Ferritin Reductions Over 3 Years
More Information
Mild-Moderate Cardiac Iron Toxicity (T2* 10 to <20 ms) Severe Cardiac Iron Toxicity (T2* <10 ms) Preventing Cardiac Iron Loading (T2* >20 ms) EPIC 1-Year
Cardiac Substudy
EU SmPC

References

  1. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE®) for up to 3 years. Abstract presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
  2. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE®) for up to 3 years. Poster presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed
Liver Iron Concentration Reductions Median Serum Ferritin Levels Liver Iron Concentration Reductions Median Serum Ferritin Levels